Motixafortide alone and in combination with natalizumab (VLA-4 inhibitor) led to robust hematopoietic stem cell (HSC) ...

Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...

Presented new data in non-human primates (NHP) for sickle cell disease (SCD), where RNA Gene Writer achieved approximately 40% and 60% of ...

The chief medical officer of Genetix Biotherapeutics, formerly known as Bluebird bio, discusses timelines and operational ...

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an ...

Sickle cell disease refers to a group of genetic diseases that impact a protein that ferries oxygen through the blood. That protein is called hemoglobin, and in sickle cell disease, aberrant ...

About 100,000 people in the U.S. have sickle cell disease, a condition that primarily affects people of color, the CDC says.

The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia ...

Lurie Children's Hospital officially announced an expansion of research with the $11 million from Don and Anne Edwards, who ...

People are often encouraged to “know their status,” however this healthy habit can be applied to more than just safe-sex practices. Although they are not the only community who suffers with sickle ...

The Ghana Institute of Clinical Genetics (GICG) successfully climaxed its 50th anniversary celebration with a grand fundraising dinner in Accra, yet the milestone event was overshadowed by an urgent ...

The global cell and gene therapy market size is valued at USD 27.02 billion in 2025 and is predicted to hit around USD 232.22 ...